Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00066352 · ClinicalTrials.gov registry record · Phase 2
Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter
A Phase 2 study, sponsored by University Health Network, Toronto.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00066352 is a Phase 2 study that has completed, run by University Health Network, Toronto.
The verdict
NCT00066352, a Phase 2 study, has completed, sponsored by University Health Network, Toronto.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying how well bortezomib works in treating patients with advanced or metastatic transitional cell cancer of the bladder, renal pelvis, or ureter.
Interventions
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00066352
The ClinicalTrials.gov registry entry for NCT00066352 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University Health Network, Toronto, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bortezomib is the first listed.
NCT00066352 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00066352 about?
NCT00066352 is a clinical study titled "Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter". RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying how well bortezomib works in treating patients with advanced or metastatic transitional cell cancer of the bladder, renal pelvis, or ureter.
What is the current status of trial NCT00066352?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-09.
What interventions are being tested in trial NCT00066352?
The interventions under investigation include: bortezomib (DRUG).
Who is sponsoring clinical trial NCT00066352?
This trial is sponsored by University Health Network, Toronto, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.